CNS neuroscience & therapeutics
December 1, 2024
Xiaoyu Niu, Yuanyuan Zheng, Wang Wang et al.
7 citations
Esketamine, a drug that blocks NMDA receptors, improved neurological function and promoted nerve repair in mice with intracerebral hemorrhage. RNA sequencing and network pharmacology identified neurotrophin-3 and the PI3K/AKT signaling pathway as key targets. Experiments confirmed that esketamine increased NTF3 protein levels, and blocking the PI3K/AKT pathway with a specific inhibitor reduced the drug's therapeutic effects. The findings suggest esketamine activates the NTF3/PI3K/AKT pathway to aid recovery after brain hemorrhage.
Neuroscience research
July 1, 2025
Kaixi Li, Nan Li, Yuanyuan Chen et al.
1 citation
Three synthetic tryptamines—AMT, 5-MeO-AMT, and 5-MeO-DiPT—alter levels of dopamine and serotonin and their metabolites in specific rat brain regions, including the prefrontal cortex, nucleus accumbens, dorsolateral striatum, and hippocampus. The effects vary by brain region and compound, with dopamine and serotonin systems playing key roles. These findings provide insight into the neurochemical actions of tryptamine hallucinogens.
Behavioural pharmacology
July 7, 2025
Kaixi Li, Nan Li, Yuanyuan Chen et al.
Three synthetic tryptamines—AMT, 5-MeO-AMT, and 5-MeO-DiPT—showed acute toxic effects, reduced movement, and triggered head-twitch responses (a sign of hallucinogenic-like behavior) in mice. Pretreatment with a low dose of M100907, a 5-HT2A receptor antagonist, blocked the head-twitch responses caused by all three substances. The findings indicate these compounds are toxic, inhibit locomotor activity, and have hallucinogenic properties, providing experimental data to support future regulation and mechanistic research.